Gore recently announced the expansion of the Gore Tag conformable thoracic stent graft with Active Control system product line, following US Food and Drug Administration (FDA) approval of four new large-diameter tapered designs: 34x28mm, 37x31mm, 40x34mm and 45x37mm.
News of the approval comes in conjunction with the first US commercial implant, completed at Keck School of Medicine of USC (Los Angeles, USA) by Sukgu Han.
For Han, the new large-diameter tapers “provide a welcome addition to the available treatment options for patients and expands applicability for the existing Gore technology,” he shared in a press release.
First approved in 2019, the Gore Tag conformable thoracic stent graft with Active Control system is indicated for the endovascular repair of all lesions of the descending thoracic aorta, including aneurysms, transections and type B dissections.
“The right device sizing is always critical,” Han emphasised, “and even more so when treating in a narrow true lumen. These additional tapered designs will help us achieve optimal sizing for a broader range of aortic diameters while continuing to leverage the proven performance and properties of this device system.”
“The Gore Tag conformable thoracic stent graft with Active Control system is an outstanding technology. I found the device to perform with reliable conformability and [a] controlled, staged delivery mechanism. And now, I know that I have the sizes I need for more of the patients I need to treat,” he concluded.
